Subscribe
istock-669281432_nataliaderiabina
NataliaDeriabina / iStockphoto.com
22 November 2017Europe

Prenatal test infringes Illumina patents, rules English High Court

A prenatal test sold by molecular diagnostics company Premaitha Health infringes patents owned by genetic sequencing firm Illumina, a UK court has ruled.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.

More on this story

Europe
Illumina files for patent infringement over prenatal test
8 September 2017   Genetic sequencing company Illumina has filed a patent infringement suit against Premaitha Health, a molecular diagnostics company, in the English High Court.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent